Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Friday that the US Food and Drug Administration (FDA) has accepted its New Drug Application for investigational oral giredestrant plus everolimus to treat adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer after prior endocrine therapy.
The agency set a Prescription Drug User Fee Act action date of 18 December 2026. The combined regimen could become the first oral selective oestrogen receptor degrader combination approved in the post-CDK4/6 inhibitor setting.
Acceptance of the filing is supported by Phase III evERA results showing the combination reduced risk of disease progression or death by 44% in the intention-to-treat (ITT) population and 62% in ESR1-mutated patients versus standard endocrine therapy plus everolimus.
CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
Pentixapharm advances preparationsfor Phase 3 PANDA study
CStone and Kimia Therapeutics collaborate to advance oncology drug candidate
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
Lytix Biopharma's ruxotemitide combination meets primary endpoint in Phase II melanoma trial
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
Genmab reports 50% reduction in risk of death in Phase 3 head and neck cancer trial
Novocure and Verastem to evaluate combination therapy for pancreatic cancer
US WorldMeds acquires Orbus Therapeutics
Astellas and Audax Biosciences sign exclusive option and licence agreement for DAX-044
Thor Medical signs three-year isotope supply agreement with Medicines Discovery Catapult